Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...

Infosecurity outlines key recommendations for CISOs and security teams to implement safeguards for AI-assisted coding ...

过去一两年，ChatGPT 等 AI 聊天工具凭借强大信息处理能力，成为工作中的 “万能顾问”，高效搞定写邮件、解疑问等需求。但面对业务执行场景，它们暴露短板：仅能提供方案，缺乏行动力、无法集成内部系统、难串联复杂流程，始终是 ...